A three-month randomized, double-blinded, clinical trial [98] investigating the effects of supplementation of 3 g of fish oil (containing 1,098 mg of EPA and 549 mg of DHA vs. a placebo) in a group of 69 men with low-burden prostate cancer demonstrated no differences in gene expression IGF-1, IGF-1 receptor, and COX2 in prostate tissue when compared to a placebo. This evidence concerns the gene IGF1 and prostate cancer.